D-Index & Metrics Best Publications
Research.com 2022 Best Scientist Award Badge

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 180 Citations 191,682 747 World Ranking 126 National Ranking 87
Best Scientists D-index 181 Citations 193,320 846 World Ranking 401 National Ranking 267

Research.com Recognitions

Awards & Achievements

2022 - Research.com Best Scientist Award

Member of the Association of American Physicians

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Immune system

His scientific interests lie mostly in Immunology, Ipilimumab, Internal medicine, Melanoma and Immunotherapy. In most of his Immunology studies, his work intersects topics such as Cytotoxic T cell. His Ipilimumab research incorporates themes from Placebo, CTLA-4, Clinical trial and Blocking antibody.

His Internal medicine study incorporates themes from Gastroenterology, Surgery and Oncology. His biological study spans a wide range of topics, including Pembrolizumab and Hazard ratio. His Melanoma research incorporates elements of Survival rate, Cohort, Pathology, Proportional hazards model and Metastasis.

His most cited work include:

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. (10003 citations)
  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (4552 citations)
  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (4552 citations)

What are the main themes of his work throughout his whole career to date?

Jedd D. Wolchok mainly investigates Internal medicine, Immunology, Melanoma, Ipilimumab and Oncology. His Cancer, Clinical trial and Advanced melanoma study in the realm of Internal medicine interacts with subjects such as In patient. His Immunology study often links to related topics such as Cytotoxic T cell.

His Melanoma research includes themes of Pembrolizumab, Phases of clinical research, Gastroenterology, Pathology and DNA vaccination. His work in Ipilimumab addresses issues such as Nivolumab, which are connected to fields such as Combination therapy. His Immunotherapy research is multidisciplinary, incorporating elements of CTLA-4 and Cancer research.

He most often published in these fields:

  • Internal medicine (44.78%)
  • Immunology (49.89%)
  • Melanoma (45.78%)

What were the highlights of his more recent work (between 2017-2021)?

  • Cancer research (27.67%)
  • Internal medicine (44.78%)
  • Immunotherapy (33.22%)

In recent papers he was focusing on the following fields of study:

Jedd D. Wolchok focuses on Cancer research, Internal medicine, Immunotherapy, Oncology and Melanoma. Jedd D. Wolchok has researched Cancer research in several fields, including Immune checkpoint, Blockade and T cell, CD8, Immune system. His study with Immune system involves better knowledge in Immunology.

In general Internal medicine study, his work on Nivolumab, Ipilimumab, Cancer and Clinical trial often relates to the realm of In patient, thereby connecting several areas of interest. Jedd D. Wolchok has included themes like Placebo and Hazard ratio in his Ipilimumab study. His Melanoma study combines topics from a wide range of disciplines, such as Discontinuation, Radiation therapy, Proportional hazards model and Cohort.

Between 2017 and 2021, his most popular works were:

  • Cancer immunotherapy using checkpoint blockade (1674 citations)
  • Cancer immunotherapy using checkpoint blockade (1674 citations)
  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline (1122 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

His primary scientific interests are in Internal medicine, Immunotherapy, Cancer research, Oncology and Melanoma. His study in Ipilimumab, Nivolumab, Clinical trial, Pembrolizumab and Cancer is done as part of Internal medicine. He focuses mostly in the field of Ipilimumab, narrowing it down to matters related to Hazard ratio and, in some cases, Placebo.

His Cancer research research integrates issues from Tumor microenvironment, Immune system, Blockade, Cancer immunotherapy and CTLA-4. His work in the fields of Lung cancer overlaps with other areas such as Text mining. Jedd D. Wolchok integrates many fields, such as Melanoma and In patient, in his works.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber.
The New England Journal of Medicine (2010)

13446 Citations

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob.
The New England Journal of Medicine (2015)

5648 Citations

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi;Naiyer A. Rizvi;Matthew D. Hellmann;Matthew D. Hellmann;Alexandra Snyder;Alexandra Snyder;Pia Kvistborg.
Science (2015)

5352 Citations

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day.
The New England Journal of Medicine (2011)

4578 Citations

Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok;Harriet Kluger;Margaret K. Callahan;Michael A. Postow.
The New England Journal of Medicine (2013)

4084 Citations

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi.
The New England Journal of Medicine (2013)

3461 Citations

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Alexandra Snyder;Vladimir Makarov;Taha Merghoub;Jianda Yuan.
The New England Journal of Medicine (2014)

3208 Citations

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Jedd D. Wolchok;Axel Hoos;Steven O'Day;Jeffrey S. Weber.
Clinical Cancer Research (2009)

2978 Citations

Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET

Héctor Peinado;Maša Alečković;Simon Lavotshkin;Irina Matei.
Nature Medicine (2012)

2838 Citations

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Michael A. Postow;Jason Chesney;Anna C. Pavlick;Caroline Robert.
The New England Journal of Medicine (2015)

2393 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Jedd D. Wolchok

Georgina V. Long

Georgina V. Long

University of Sydney

Publications: 283

Paolo A. Ascierto

Paolo A. Ascierto

National Institutes of Health

Publications: 233

Dirk Schadendorf

Dirk Schadendorf

University of Duisburg-Essen

Publications: 226

Caroline Robert

Caroline Robert

Institut Gustave Roussy

Publications: 182

F. Stephen Hodi

F. Stephen Hodi

Harvard University

Publications: 182

Richard A. Scolyer

Richard A. Scolyer

Royal Prince Alfred Hospital

Publications: 180

Douglas B. Johnson

Douglas B. Johnson

Vanderbilt University Medical Center

Publications: 171

Antoni Ribas

Antoni Ribas

University of California, Los Angeles

Publications: 168

Keith T. Flaherty

Keith T. Flaherty

Harvard University

Publications: 167

Reinhard Dummer

Reinhard Dummer

University of Zurich

Publications: 162

Mark J. Smyth

Mark J. Smyth

QIMR Berghofer Medical Research Institute

Publications: 158

Alexander M. Menzies

Alexander M. Menzies

University of Sydney

Publications: 157

Guido Kroemer

Guido Kroemer

Sorbonne University

Publications: 153

Alexander M.M. Eggermont

Alexander M.M. Eggermont

Erasmus University Rotterdam

Publications: 151

James Larkin

James Larkin

Royal Marsden NHS Foundation Trust

Publications: 145

John M. Kirkwood

John M. Kirkwood

University of Pittsburgh

Publications: 141

Trending Scientists

Tom Rodden

Tom Rodden

University of Nottingham

Piero Fraternali

Piero Fraternali

Politecnico di Milano

Wei Liu

Wei Liu

Harbin Institute of Technology

Elio Santacesaria

Elio Santacesaria

University of Naples Federico II

Adilson J. Curtius

Adilson J. Curtius

Universidade Federal de Santa Catarina

Stergios Logothetidis

Stergios Logothetidis

Aristotle University of Thessaloniki

Werner J. Blau

Werner J. Blau

Trinity College Dublin

Richard G. Hoagland

Richard G. Hoagland

Los Alamos National Laboratory

Olivier Tenaillon

Olivier Tenaillon

Université Paris Cité

Jerry L. Workman

Jerry L. Workman

Stowers Institute for Medical Research

Philippe Soriano

Philippe Soriano

Icahn School of Medicine at Mount Sinai

Richard Vandlen

Richard Vandlen

Genentech

Thomas T. Chen

Thomas T. Chen

University of Connecticut

Bastiaan Willem Ibelings

Bastiaan Willem Ibelings

University of Geneva

Koji Matsuo

Koji Matsuo

Yamaguchi University

Todd F. Heatherton

Todd F. Heatherton

Dartmouth College

Something went wrong. Please try again later.